Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rhythm Pharmaceuticals ( (RYTM) ) has provided an update.
On December 16, 2025, Rhythm Pharmaceuticals announced that board member Camille L. Bedrosian, M.D. resigned from the company’s Board of Directors, effective immediately. Bedrosian, who served on the Compensation & Management Development Committee and the Governance and Nominating Committee, left her roles without any disagreement related to the company’s operations, policies or practices, suggesting the departure is not expected to signal governance or strategic conflict for stakeholders.
The most recent analyst rating on (RYTM) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.
Spark’s Take on RYTM Stock
According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.
Rhythm Pharmaceuticals’ overall stock score is driven by strong technical indicators and positive corporate events, such as promising trial results and regulatory progress. However, financial performance and valuation remain weak due to ongoing profitability challenges and a negative P/E ratio. The earnings call provided a positive sentiment, highlighting revenue growth and strategic initiatives, which slightly offset the financial weaknesses.
To see Spark’s full report on RYTM stock, click here.
More about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity, targeting patients with severe, life-threatening metabolic conditions.
Average Trading Volume: 744,039
Technical Sentiment Signal: Buy
Current Market Cap: $7.47B
See more data about RYTM stock on TipRanks’ Stock Analysis page.